top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Recent Biopharma Funding Activity - April 1st

Check out the following recent activity in the biopharma funding space. This mix of private investments and public grants fuels important research and development across the industry. Take a closer look at some of the notable updates for this week:

– Private Funding –

Avenzo Therapeutics, Inc.

💸 $346M equity funding through Series A-1 funding w/ $223M already sold.

Volumina Medical

💸 Received $21M Series A funding to gather additional and valuable clinical data from AdipearlTM studies.

Edgewood Oncology

💸 Secures $20M in Series A funding from Alta Partners to fund BTX-A51 development.


💸 Received CHF 14M (~$15.4M) Series B2 funding led by Belmondo to fund its clinical trials.

Aeovian Pharmaceuticals

💸 Raised $50M funding led by Apollo Health Ventures and other investors to support the completion of Ph1 trial of AV078 and prepare to initiate Ph2 clinical trial.

Firefly Bio, Inc.

💸 $72M equity funding w/ $39.9M already sold.

IntraBio Inc.

💸 $40.9M equity funding w/ $40.2M already sold.


💸 Raised €4.4M (~$4.7M) funds to finance the execution of the ReActIF-ICE trial of the ARTICE® therapy.

GelMEDIX, Inc.

💸 $3.5M debt financing w/ $1.8M already sold.

– Grant Funding –

Confo Therapeutics

🏦 Secured €1.6M (~$1.7M) VLAIO grant to support the R&D of the next-generation medicines targeting Class B GPCRs.

Neogap Therapeutics

🏦 SEK 5M (~$463K) awarded by Eurostars to develop an assay of T-cell activity in collab w/ Okomera.

– Post-IPO/Public Funding –

United Therapeutics Corporation

🏦 Entered a $1B accelerated share repurchase program agreement w/ Citibank, N.A.


🏦 Secured $750M funding from Blackstone Life Sciences to develop flu shots.


🏦 $240M underwritten offering to fund its NKX019 clinical development, build manuf. capabilities and for general corporate purposes.

Merrimack Pharmaceuticals

🏦 Received $225M milestone payment from Ipsen due to ONIVYDE FDA approval.

Praxis Precision Medicines, Inc.

🏦 $200M public offering.

Avalo Therapeutics

🏦 $185M private placement financing.


🏦 $149.4M private placement financing led by RA Capital Management to fund the R&D of neflamapimod, working capital, and general corporate purposes.

Aquestive Therapeutics

🏦 Closed $75M underwritten public offering.


🏦 $15M PIPE financing participated by ADAR1 Capital Management and other investors to be used for general corporate purposes, including research and development and working capital.

Xilio Therapeutics

🏦 $11.3M private placement led by Bain Capital Life Sciences and Rock Springs Capital to fund the development of XTX301 as well as XTX101.

Molecular Templates

🏦 $9.5M private placement led by BVF Partners L.P. and other investors to fund its ongoing clinical studies, working capital, and general corporate purposes.

Portage Biotech

🏦 Raised 2.8M of non-dilutive funding to further develop its PORT-6 Phase 1a portion of the ADPORT-601 trial.


Get a list of all recently funded companies with deeper info to help your sales/BD activities. Contact us to learn more

Article History:

RF, DV (04/01/24)


bottom of page